Drugs / rFVIII-FS
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT00623727 Comparator | Jun 2008 → Apr 2010 | hemophilia A | Bayer | Terminated | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rFVIII-FS | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00623727 ↗ |
| Known as | BAY14-2222 | “rFVIII-FS/WFI (BAY14-2222)” NCT00623727 ↗ |
| Modality | Protein / enzyme biologic | “recombinant FVIII” PMID 20059562 ↗ Jan 2010 |
| Route | Intravenous | “25 IU/kg body weight intravenous 3x/week for 52 weeks” NCT00623727 ↗ |